×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AVIR – atea pharmaceuticals, inc. - common stock (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AVIR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/5
06:54 pm
avir
Atea Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Atea Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
3/5
04:31 pm
avir
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
3/5
04:05 pm
avir
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Medium
Report
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2/26
07:32 am
avir
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026 [Yahoo! Finance]
Low
Report
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026 [Yahoo! Finance]
2/26
07:00 am
avir
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026
Low
Report
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026
2/24
07:00 am
avir
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
Low
Report
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
1/23
05:06 am
avir
Atea Pharmaceuticals (NASDAQ:AVIR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
High
Report
Atea Pharmaceuticals (NASDAQ:AVIR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
1/13
01:56 pm
avir
Bullish Atea Pharmaceuticals Insiders Loaded Up On US$5.40m Of Stock [Yahoo! Finance]
Low
Report
Bullish Atea Pharmaceuticals Insiders Loaded Up On US$5.40m Of Stock [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
3/5/2026
04:05 pm
AVIR
atea pharmaceuticals, inc. - common stock
MISS
Report
1.2%
atea pharmaceuticals, inc. - common stock
11/12/2025
04:05 pm
AVIR
atea pharmaceuticals, inc. - common stock
MISS
Report
-12.0%
atea pharmaceuticals, inc. - common stock
8/7/2025
04:05 pm
AVIR
atea pharmaceuticals, inc. - common stock
BEAT
Report
-2.3%
atea pharmaceuticals, inc. - common stock
5/12/2025
04:11 pm
AVIR
atea pharmaceuticals, inc. - common stock
BEAT
Report
-11.1%
atea pharmaceuticals, inc. - common stock
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/5
04:51 pm
avir
Form 10-K Atea Pharmaceuticals, For: Dec 31
Medium
Report
Form 10-K Atea Pharmaceuticals, For: Dec 31
3/5
04:11 pm
avir
Form 8-K Atea Pharmaceuticals, For: Mar 05
Medium
Report
Form 8-K Atea Pharmaceuticals, For: Mar 05
2/9
02:02 pm
avir
Form SCHEDULE 13G Atea Pharmaceuticals, Filed by: BML Investment Partners, L.P.
Low
Report
Form SCHEDULE 13G Atea Pharmaceuticals, Filed by: BML Investment Partners, L.P.
2/3
07:53 pm
avir
Form 4 Atea Pharmaceuticals, For: Jan 31 Filed by: Horga Maria Arantxa
Low
Report
Form 4 Atea Pharmaceuticals, For: Jan 31 Filed by: Horga Maria Arantxa
2/3
07:47 pm
avir
Form 4 Atea Pharmaceuticals, For: Jan 31 Filed by: Vavricka John
Low
Report
Form 4 Atea Pharmaceuticals, For: Jan 31 Filed by: Vavricka John
2/3
07:47 pm
avir
Form 4 Atea Pharmaceuticals, For: Jan 31 Filed by: Hammond Janet MJ
Low
Report
Form 4 Atea Pharmaceuticals, For: Jan 31 Filed by: Hammond Janet MJ
2/3
07:46 pm
avir
Form 4 Atea Pharmaceuticals, For: Jan 31 Filed by: Sommadossi Jean-Pierre
Low
Report
Form 4 Atea Pharmaceuticals, For: Jan 31 Filed by: Sommadossi Jean-Pierre
2/3
07:46 pm
avir
Form 4 Atea Pharmaceuticals, For: Jan 31 Filed by: Corcoran Andrea
Low
Report
Form 4 Atea Pharmaceuticals, For: Jan 31 Filed by: Corcoran Andrea
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/7
Form 425 Aviragen Therapeutics, Filed by: Aviragen Therapeutics, Inc.
20.6%
1/12 Form 8-K Aviragen Therapeutics, For: Jan 11 13.6%
11/29 Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma 10.2%
1/17 Form 425 Aviragen Therapeutics, Filed by: Aviragen Therapeutics, Inc. 4.8%
11/7 Form 10-Q Aviragen Therapeutics, For: Sep 30 3.8%
2/6 Form 8-K Aviragen Therapeutics, For: Feb 06 3.3%
1/3 Form 424B3 Aviragen Therapeutics, 2.7%
2/7 Aviragen and Vaxart Amend Terms of Merger Agreement to Increase the Value for Aviragen Stockholders 2.0%
11/6 Aviragen Therapeutics, Inc. (NASDAQ: AVIR) had its "hold" rating re-affirmed by analysts at HC Wainwright. 1.8%
12/12 Form S-4 Aviragen Therapeutics, 1.7%
1/12 Form 8-K Aviragen Therapeutics, For: Jan 11 13.6%
11/29 Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma 10.2%
1/17 Form 425 Aviragen Therapeutics, Filed by: Aviragen Therapeutics, Inc. 4.8%
11/7 Form 10-Q Aviragen Therapeutics, For: Sep 30 3.8%
2/6 Form 8-K Aviragen Therapeutics, For: Feb 06 3.3%
1/3 Form 424B3 Aviragen Therapeutics, 2.7%
2/7 Aviragen and Vaxart Amend Terms of Merger Agreement to Increase the Value for Aviragen Stockholders 2.0%
11/6 Aviragen Therapeutics, Inc. (NASDAQ: AVIR) had its "hold" rating re-affirmed by analysts at HC Wainwright. 1.8%
12/12 Form S-4 Aviragen Therapeutics, 1.7%
TOP News Decliners
2/13
Form SC 13G/A Aviragen Therapeutics, Filed by: Broadfin Capital, LLC
-8.7%
2/9 BRIEF-Aviragen Adjourns Special Meeting Of Stockholders [Reuters] -7.3%
2/1 Form 425 Aviragen Therapeutics, Filed by: Aviragen Therapeutics, Inc. -7.1%
2/6 Aviragen Adjourns Special Meeting of Stockholders Until February 9, 2018 -6.0%
12/29 Form SC 13D Aviragen Therapeutics, Filed by: DIGIRAD CORP -5.2%
1/29 Form DFAN14A Aviragen Therapeutics, Filed by: DIGIRAD CORP -4.7%
1/12 Form PREC14A Aviragen Therapeutics, Filed by: DIGIRAD CORP -4.4%
1/18 Form SC 13D/A Aviragen Therapeutics, Filed by: SC Fundamental Value Fund, L.P. -4.3%
1/24 Form DFAN14A Aviragen Therapeutics, Filed by: DIGIRAD CORP -3.0%
11/9 Form SC 13D/A Aviragen Therapeutics, Filed by: SC Fundamental Value Fund, L.P. -2.7%
2/9 BRIEF-Aviragen Adjourns Special Meeting Of Stockholders [Reuters] -7.3%
2/1 Form 425 Aviragen Therapeutics, Filed by: Aviragen Therapeutics, Inc. -7.1%
2/6 Aviragen Adjourns Special Meeting of Stockholders Until February 9, 2018 -6.0%
12/29 Form SC 13D Aviragen Therapeutics, Filed by: DIGIRAD CORP -5.2%
1/29 Form DFAN14A Aviragen Therapeutics, Filed by: DIGIRAD CORP -4.7%
1/12 Form PREC14A Aviragen Therapeutics, Filed by: DIGIRAD CORP -4.4%
1/18 Form SC 13D/A Aviragen Therapeutics, Filed by: SC Fundamental Value Fund, L.P. -4.3%
1/24 Form DFAN14A Aviragen Therapeutics, Filed by: DIGIRAD CORP -3.0%
11/9 Form SC 13D/A Aviragen Therapeutics, Filed by: SC Fundamental Value Fund, L.P. -2.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: